Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized,...

Area of Science:

• Nephrology
• Emergency Medicine
• Pharmacology

Background:

• Hyperkalemia is a serious condition requiring prompt treatment.
• Sodium zirconium cyclosilicate (SZC) is an approved selective potassium binder.
• Evaluating SZC in combination with insulin and glucose for acute hyperkalemia in the ED.

Purpose of the Study:

• To explore the efficacy of SZC with insulin and glucose in treating hyperkalemia in the emergency department.
• To assess the change in serum potassium levels over time.

Main Methods:

• Phase II, randomized, double-blind, placebo-controlled study.
• Adult ED patients with serum potassium ≥ 5.8 mmol/L received SZC 10g or placebo with insulin and glucose.
• Primary outcome: mean change in serum potassium from baseline to 4 hours.

Main Results:

• SZC showed a greater reduction in serum potassium at 2 hours compared to placebo.
• Mean serum potassium change from baseline to 4 hours was -0.41 mmol/L for SZC vs. -0.27 mmol/L for placebo.
• A numerically lower proportion of SZC patients required additional potassium-lowering therapy.

Conclusions:

• This pilot study suggests SZC with insulin and glucose may offer incremental benefit in emergency hyperkalemia treatment.
• SZC appears to be a safe and potentially effective adjunct therapy.
• Further research is warranted to confirm these findings.